| C - Cardiovascular System | This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.
|
| | C02 - Antihypertensives | See also C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers and C09 - Agents acting on the renin-angiotensin system.
Antihypertensives are mainly classified at 3rd levels according to the mechanism of action. Most headings are self-explanatory:
C02A Antiadrenergic agents, centrally acting
C02B Antiadrenergic agents, ganglion-blocking
C02C Antiadrenergic agents, peripherally acting
C02D Arteriolar smooth muscle, agents acting on
C02K Other antihypertensives
C02L Antihypertensives and diuretics in combination
C02N Combinations of antihypertensives in ATC gr. C02
| The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.
Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).
|
| | C02C - Antiadrenergic Agents, Peripherally Acting | Alpha- and beta-blocking agents, see C07AG.
|
| | C02CA - Alpha-Adrenoreceptor Antagonists | Combinations with diuretics, see C02LE - Alpha-adrenoreceptor antagonists and diuretics.
Alfuzosin and terazosin are classified in G04CA.
|
| | C02CA06 - Urapidil | | Concentr. | Adm.Route | Note |
|---|
| | P | | | | O | |
|
|
|
